Optimising DNA Vaccinations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 15, 2015

Primary Completion Date

May 10, 2017

Study Completion Date

April 10, 2018

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

CN54ENV DNA

"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."

BIOLOGICAL

GENEVAX® IL-12 DNA

"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Imperial College London

OTHER

NCT03663998 - Optimising DNA Vaccinations in Healthy Volunteers | Biotech Hunter | Biotech Hunter